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Summary.-RNA extracted from the spleens of tumour-bearing (TLRNA) and
tumour-immune (ILRNA) mice was shown to transfer to normal lymphocytes
(NL) the ability to produce factors that blocked specific tumour-cell cytotoxicity and
mediated specific antibody-dependent cell cytotoxicity (ADCC). Aliquots of normal
C3H mouse lymphocytes were treated with TLRNA or ILRNA and cultured in vitro
in the absence of tumour antigen. Supernatants were collected at 24h intervals and
tested in a microcytotoxicity assay for blocking and ADCC activities. Factors that
inhibited tumour destruction by specifically sensitized lymphocytes at the level of
both the tumour cells and effector cells were demonstrable in culture supernatants
of NL pretreated with TLRNA (50 or 100 /jg/4x 106 cells) but not ILRNA. However,
treatment of NL with either RNA resulted in the production of factors that mediated
tumour-specific ADCC. Cytotoxicity testing and absorption studies of the tumour
cell and a control cell (LM) indicated that factors mediating ADCC and blocking at
the target-cell level were specific for the tumour. Suppressor activity at the effector-
cell level was not absorbed by tumour cells and represents a separate and distinct
mechanism ofimmunosuppression. These data indicate that RNA faithfully transfers
''suppressive" as well as "positive" types of immune responses that have been
reported previously for lymphocytes obtained directly from tumour-bearing and
tumour-immune animals.
OUR LABORATORY and others have
demonstrated the ability to transfer
humoral and cell-mediated immune re-
sponses to normal lymphocytes in vitro
and in vivo by treatment with RNA ex-
tracted from the lymphoid tissue of
immunized animals. Documented RNA-
mediated transfers have been described in
various antigen systems such as sheep red
blood cells (Abramoff & Brum, 1968; Bell
& Dray, 1973) tuberculin (Dodd et al.,
1973; Thor & Dray, 1973) allogenic tissue
(Mannick & Egdahl, 1964) and tumours
(Alexander et al., 1967; Dodd et al., 1973;
Kern et al., 1976; Kern & Pilch, 1974;
Thor & Dray, 1973). These earlier investi-
gations were based entirely on the transfer
of "positive" types of immune responses,
in which lytic antibody (Abramoff &
Brum, 1968; Bell & Dray, 1973) skin-test
reaction (Han, 1973) production of
migration-inhibitory factor (Dodd et al.,
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1973; Kern et al., 1976; Thor & Dray,
1973) lymphoblastogenesis (Deckers et al.,
1975; Dodd et al., 1973) cytotoxic T-cells
(Alexander et al., 1967; Dodd et al., 1973;
Kern & Pilch, 1974) and protection against
tumours (Alexander et al., 1967; Kennedy
et al., 1969; Ramming & Pilch, 1970;
Rigby, 1969; Schlager et al., 1975) were
demonstrated. Credence for these studies
is dependent upon the demonstration of
antigenic specificity for the transferred
response. In a recent report from our
laboratory, Greenup et al. (1978) using
multiple criss-cross experiments with
RNA directed at a variety of normal and
tumour cell lines, demonstrated that the
RNA-transferred cytotoxic response was
specific for the eliciting antigen. Similar
specificity studies have been made by in-
vestigators for many other "positive"
types of responses transferred with
RNA.
Since suppression of the immune re-
sponse by soluble factors has become an
important and provocative area of re-
search, we began to investigate the
possibility of transferring "negative" or
"suppressive" types of immune activity
with RNA. An animal tumour model was
a logical choice in which to initiate such
studies, since "positive" and "suppres-
sive" immune responses have been re-
ported. Investigators have demonstrated
similar "positive" immunological re-
sponses in tumour-immune and tumour-
bearing animals such as complement
(C')-dependent cytolytic antibody (Bansal
& Sjogren, 1971; Hellstrom et al., 1968;
Wood & Morton, 1970) C'-independent
lymphocyte-dependent cytotoxic antibody
(ADCC) (Pollack, 1973; Pollack et al.,
1972) and cytotoxic T-cells (Hellstrom,
1967; Hellstrom et al., 1971; Sjogren &
Borum, 1971). However, the response in
the tumour-bearing host also includes
"blocking" or "enhancing" factors, vari-
ously described as antibody (Takasugi &
Klein, 1971) antigen (Currie & Basham,
1972) or soluble complex of both (Sjogren
et al., 1971) and "suppressor" factors re-
leased by suppressor cells which effectively
abolish the action of specifically sensitized
lymphocytes at the level of either the
target cell or the effector cell. Production
ofthe former (Nelson et al., 1 975a) and the
latter (Pope et al., 1976; Takei et al., 1976)
have been demonstrated in vitro by cul-
turing splenic lymphocytes from
tumour-bearing animals. In a compara-
tive study, Nelson et al. (1975a, 1975b)
showed that while lymphocytes from
tumour-immune (IL) and tumour-bearing
(TL) mice could produce ADCC antibody
in culture, only TL could produce "block-
ing" factors. Pope et al. (1976) and Takei
et al. (1976) found that suppressor cells
isolated from the spleens of tumour-
bearing animals elaborated factors that
suppressed specific and nonspecific im-
munological responses at the level of the
lymphocyte. Since the spleen was the
source of "blocking" and "suppressor"
activities in these studies, and the spleen
serves as a source of RNA in our studies,
we assumed that the information neces-
sary to transfer "suppressive" responses
was contained in our RNA preparations.
The transfer ofsuch distinctive suppressor
activities would provide additional evi-
dence for the hypothesis that "immune"
RNA acts as an informational molecule as
others have suggested (Bilello et al., 1976;
Dodd et al., 1973; Greenup et al., 1978).
The results from this study indicated
that normal lymphocytes treated with
RNA isolated from spleens of tumour-
bearing mice (TLRNA) released soluble
factors that "suppressed" cell-mediated
immunity at the effector-cell and target-
cell levels. The phenomenon was found to
be unique to TLRNA and not an artefact,
since RNA from spleens of immune
animals transferred only "positive" im-
munological responsiveness.
MATERIALS AND METHODS
Animals.-Inbred male C3H/HeJ mice,
6-8 weeks old, were obtained from Jackson
Laboratories, Bar Harbor, Maine and used
in all studies.
Cell lines. All the cell lines used in this
investigation w%ere of C3H mouse origin.
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They included the 4198, the 4198V and the
LM cells. The 4198 tumour cell originated
from the transformation of C3H cells with an
LID strain of the polyoma virus (Ting &
Law, 1965). These cells give rise to tumours
in C3H mice by 14 days after i.m. injection
of2-5 x 104 cells. The tumour, a fibrosarcoma,
has been shown to be free of demonstrable
virus by haemagglutination inhibition and
plaque-formation assays (Ting & Law, 1965).
The 4198V cell, a variant of 4198, arose
during in vitro passage (Ting et al., 1972). The
tumour-associated antigen of 4198V, deter-
mined by isotopic antiglobulin absorption,
was 8 8xthat in the 4198 cells (Ting et al.,
1972) making it well suited for immunization
and in vitro cytotoxicity measurements. The
LM cell was cloned from L-cells by Kuchler
& Merchant (1956). This syngeneic, non-
tumorigenic cell is capable of eliciting an
immune response in C3H mice and served as
a control in this study.
All cells were maintained as monolayer
cultures in RPMI-1640 containing 10% heat-
inactivated foetal calf serum (56°C for 30
min) and 2 mm L-glutamine (Grand Island
Biological Company, Grand Island, New
York).
Sources of RNA and lymphocytes.-RNA
and lymphocytes were obtained from tumour-
bearing or 4198V-immunized and LM-immun-
ized animals. Tumours were induced by i.m.
injection of 5 x 104 4198 cells, suspended in
serum-free RPM1-1640, into one hind leg of
C3H mice. Palpable tumours appeared in
all mice within 10-12 days. Spleens were
harvested from mice 5-7 days after tumour
appearance. Iflymphocytic RNA was desired,
the spleens were immediately frozen in a
dry-ice/acetone bath and stored at -70°C
until RNA extraction. Lymphocytes used
directly for culturing were teased free of the
splenic capsule in RPM1-1640, separated from
red cells and granulocytes using Ficoll-
Hypaque according to Boyum (1968), washed
and resuspended to desired concentrations.
The methods for immunizing C3H mice
against the 4198V tumour cell and the LM
cell were as described in a previous paper
(Greenup et al., 1978). RNA and lymphocytes
were harvested from the spleens of immune
animals as described above. Lymphocytes
from 4198V-immune mice were also used as
effector cells in all cytotoxicity assays.
Control RNA and lymphocytes were
obtained from normal untreated animals.
RNA extraction.-RNA was extracted
from the frozen mouse spleens (10-12 per
extraction) using a modified biphasic extrac-
tion in hot phenol as described in a previous
paper (Dodd et al., 1973). We have shown
that the extracted RNA exhibits a character-
istic 3-peak profile (5S, 18S and 28S) on
sucrose-density gradients (Dodd et al., 1973;
Greenup et al., 1978). The low-molecular-
weight (4-6S) RNA contains transfer RNA,
the second peak (12-20S) comprises mRNA
and smaller ribosomal RNA, and the larger-
molecular-weight (20-35S) RNA accounts for
larger ribosomal RNA. Previous investiga-
tions using fractionation studies have demon-
strated that the immunologically active
components of the total cellular RNA were
confined to the 10-16S sedimentation range
(Bilello et al., 1976; Dodd et al., 1973; Kern
etal., 1976). Inthisstudynormallymphocytes
were treated with specific amounts of whole
unfractionated RNA.
RNA treatment of lymphocytes.-RNA ex-
tracted from the splenic lymphocytes of
normal (NLRNA), tumour-bearing (TLRNA),
tumour-immune (ILRNA) and LM-immun-
ized (LMRNA) mice was used to treat normal
C3H mouse lymphocytes (NL). The procedure
for RNA treatment has been described in
detail in a previous paper (Greenup et al.,
1978). After treatment, the cells were washed
and resuspended to a concentration of 5-8x
106 lymphocytes/ml in RPMI-1640 supple-
mented with 20% heat-inactivated foetal
calfserum, 2 mm L-glutamine, 25 mmHEPES
(Sigma Chemical Company, St Louis, Mis-
souri) and 100 jg/ml gentamicin (Schering
Corporation, Kenilworth, N.J.).
Lymphocyte culturing.-A system free of
specific antigen was developed in order to
detect factors released by RNA-treated
lymphocytes maintained in continuous cul-
ture. The procedure was a modification ofthe
method used by Nelson et al. (1975a).
Suspensions of RNA-treated lymphocytes
(5-8 x 106/ml) were added to 25ml Erlen-
meyer flasks in 5ml volumes and incubated
in the absence ofantigen at 37°C in a humidi-
fied atmosphere containing 5% C02. Super-
natants were collected at 24h intervals by
transferring the cell suspensions to sterile
tubes and centrifuging at 250 g for 6 min.
The supernatants were removed, filtered,
heat-inactivated and stored at -20°C. The
cell pellets were resuspended in fresh culture
medium and reincubated. Lymphocytes from
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spleens of normal (NL), tumour-bearing
(TL), tumour-immune (IL) and LM-immun-
ized (ILM) mice were maintained in the same
manner. Viability of lymphocytes was asses-
sed at each interval ofsupernatant collection.
Microcytotoxicity assay.-A modification
of the Takasugi & Klein (1970) microcyto-
toxicity assay developed in our laboratory
has been described in detail by Greenup et
al. (1978). Briefly, 4198V tumour cells were
seeded into wells (100/well) of 3034 micro-
cytotoxicity plates (Falcon Plastics, Cherry
Hill, N.J.). The tumour cells were allowed to
attach for 12 h, after which specifically
immune lymphocytes were added to the wells
at an effector cell:target cell ratio of 100:1.
After an additional 40 h of incubation the
remaining tumour cells were washed, fixed
with acetone-alcohol and stained with crystal
violet. The cells in the wells of each test row
were counted and averaged. The percent
cytotoxicity (%C) was calculated as follows:
(Mean number (Meannumber
oftumour cells oftumour cells
left in control left in test
%C=wells) wells) - 100 /° (Mean number oftumour cells left
in control wells)
Blocking assay.-Supernatants from the
various lymphocyte cultures were tested for
their capacity to block the cytotoxic action
ofspecifically tumour-sensitized lymphocytes.
Microcytotoxicity plates were seeded with
tumour cells as described above. Before the
addition of effector cells, 0 01 ml of the
various supernatants was added to the
appropriate wells and remained in contact
with the tumour cells for 30 min. The super-
natants were decanted and cytotoxic lympho-
cytes added. After 40 h of incubation the
tests were terminated and the cytotoxicity
determined as described previously. The
percent blocking (%B) was calculated as
follows:
(%C inthe (%C in the
control - test
0/B=supernatants) supernatants) X 100
(%C in the control
supernatants)
ADCC assay.-The ability of the culture
supernatants to induce tumour-cell cyto-
toxicity by normal lympoheytes was deter-
mined. The experimental protocol was the
same as that described for blocking, with the
exception of using normal, nonsensitized
lymphocytes as effector cells. The %
ADCC was calculated as follows:
%ADCC=
(Mean (Mean
number of number of
tumour cells tumour cells
in wells with inwells with
control test
supernatants) supernatants) X 100
(Mean number of tumour
cells in wells with control
supernatants)
Specificity of RNA-induced supernatant
activity.-Tumourspecificity oftheelaborated
factors was determined in two ways. First,
criss-cross experiments were done for all of
the above assays, and used the control LM
cell (as a target cell) and supernatants from
LM-immune lymphocytes and normal lym-
phocytes treated with LMRNA. Secondly,
absorption studies were made by incubating
2 ml of the supernatants from cells treated
with tumour-specific ILRNA or TLRNA
with 107 tumour cells or LM cells for 45 min
at 37TC. The supernatants were centrifuged
free of cells, filtered and retested for blocking
and ADCC activity.
Treatment of effector cells with supernatants.
-In order to determine the effect of super-
natants on the cell-mediated cytotoxic re-
sponse at the effector-cell level, tumour-
immune lymphocytes were incubated for 30
min in 2 ml of the various supernatants. The
lymphocytes were then washed x3 in
serum-free medium, resuspended in complete
medium (106/ml) and tested on plated 4198V
cells to assess cytotoxic potential as described
above.
Analysis of data.-The data presented in
this study represent the results oftwo experi-
ments. All experiments were repeated at
least 3-4 times in order to establish the
reproducibility of the systems. Statistical
analysis of the data was by Student's t test.
RESULTS
Viability of cultured lymphocytes
It was realised initially that the viability
of RNA-treated cells in an antigen-free
culture would be a limiting factor in the
time span of the experiments. As is shown
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NL treated with:
1004 50pg TLRNA 100 g TLRNA 100 5S9 ILRNA 100,Ug NLRNA
SC
Untreated
TL
100-
IL NL
kL
I 94 sr I r- I W I Fr r^ cs IT Iw N wI ,p V .N .X MI
Culture time (h)
FIG. 1.-Viability of untreated lymphocytes
(TL, IL and NL) and normal lymphocytes
treated with tumour-specific RNA (TLRNA
and ILRNA) at 24h intervals of culture. %
viability was determined by trypan-blue
dye exclusion/100 cells. Columns represent
the mean of 6 counts from 2 experiments.
Three repetitions of this experiment
yielded similar results.
in Fig. 1, 74-830% of splenic lymphocytes
from tumour-bearing (TL) or tumour-
immune (IL) mice remained viable for
4 days, whilst less than 5000 of normal
lymphocytes (NL) survived for 48 h under
the same conditions. Fig. 1 also shows that
treatment of NL with tumour-specific
RNA from immune or tumour-bearing
mouse spleens (ILRNA or TLRNA), in
50,ug or lOO1g quantities, increased the
viability from 43% to 68-85% at 48 h,
whereas treatment with RNA from normal
mouse spleens (NLRNA) had no detect-
able effect on lymphocyte viability (40%
at 48 h). It is possible that RNA from
sensitized lymphocytes may provide some
of the information responsible for the
sustained viability of these cells under
these conditions.
Demonstration of blocking activity in
supernatants
Supernatants from untreated and RNA-
treated cells collected at 24, 48, 72 and 96 h
of culture were tested simultaneously for
the presence of factors capable of abro-
gating the cytotoxic action of tumour-
immune lymphocytes (IL) at the tumour-
cell level. Table I summarizes the results
of 2 experiments and illustrates the cyto-
toxicity of supernatant-exposed or un-
exposed tumour cells by IL. The data indi-
cate that treatment of normal lympho-
cytes (NL) with RNA extracted from
spleens oftumour-bearing mice (TLRNA),
in 50,ug or lOO1g quantities, produced
supernatants containing blocking activity,
as illustrated by a marked reduction of
cytotoxicity by IL (24-72 h supernatants)
when compared to control supernatants
(from NL treated with NLRNA). The
blocking effect was also demonstrable
with supernatants from lymphocytes
taken directly from tumour-bearing
animals (TL) which has been reported by
Nelson et al. (1975a). It is interesting to
note that the observed blocking activity
produced by TLRNA-treated cells was
detectable earlier (24 h compared to 48 h)
and present in greater amounts (59.3-
60.7% blocking compared to 34.6-41.9%)
than that produced by TL, although pro-
duction by the latter was more sustained,
possibly due to their longer survival. The
last significant blocking activity produced
by TLRNA-treated cells coincides fairly
well with the 50% loss ofviability (Fig. 1).
The generation of blocking activity by
TLRNA-treated lymphocytes was found
to be a reproducible event throughout
this study, and in 4 additional experi-
ments.
Table I also illustrates the lack of
blocking activity in supernatants from
NL treated with splenic RNA from
tumour-immune mice (ILRNA) or from
lymphocytes taken directly from these
animals (IL). Instances of high "negative
blocking activity" (as great as -30.9%
by IL at 72 h) could possibly represent
increased cytotoxic activity attributed to
.A.Mi.2 A.
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TABLE II.-ADCC activity associated with supernatants from RNA-treated and tumour-
sensitized lymphocytes
Effector Supernatant Tumour cells/well remaining % ADCC
cell from (Mean±s.e.)'
NL none 57±5
NL
treated with:
100 jig NLRNA
100 pg ILRNA
100 Hg TLRNA
Untreated:
NL
IL
TL
After exposure to supernatant and NL
I As
24 48
53±4 59±4
35±3 35±4
31±3 43±4
55±5
48±4
50±5
55±4
34±3
40±3
72
57±3
49±3
51±5
53+4
28±2
30±2
962
nd3
nd
nd
58±4
34±3
31±2
24 48 72 96
RNA-treated control
33-9* 40-7* 14-0
41-5* 27-lt 10-5 -
Untreated control
12-7 38-2* 47-2*
9-0 27-3t 43-4*
41-4*
46.5*
1 Mean of 20 replicate wells.
2 Hour of culture that supernatants were collected.
3 Not done.
*P<0.01.
tP<0.05.
TABLE III.-Tumour-cell specificity ofsupernatantfactors miediating blocking and ADOC
Target
cells Supernatant from
NL
Treated with:
4198V 100 Zg NLRNA
100 ug ILRNA
50 ,ug TLRNA
100 ug TLRNA
100 ,ug LMRNA
Untreated:
NL
IL
TL
ILM
NL
Treated with:
LM 100 ug NLRNA
100 Mug ILRNA
50 Mg TLRNA
100 Mug TLRNA
100 Mg LMRNA
Untreated:
NL
IL
TL
ILM
Target cells/welll
remaining after exposure
to supernatant and:
(Mean±s.e.)
NL ILb %C2
NL IL byIL
66±44
46±4
nd5
47±3
69±4
68±5
42±4
45±4
66±5
NL
82±6
79±4
nd
81±5
57±4
82±5
80±4
84±4
54±4
39±3
34±3
55±4
53±4
37±3
38±3
28±2
51±4
35±3
ILM
50±5
52±4
53±4
52±4
45±3
50±5
49±3
51±4
47±3
409
48-4
16-6
19-7
43-9
44-1
58-8
25-0
48-5
by ILM
390
36-6
35-4
36-6
40-2
40-2
41-5
37-8
42-7
% B6 % ADCC
-18-3
59-4*
51-8*
-7-3
-33-3
43-3*
-9-8
6-1
9-2
6-1
-15-6
-3-2
5-9
-6-2
30.3*
nd
28-8*
-4.5
38-2*
33-8*
2-9
3-6
nd
1-2
30.5*
2-4
-2-4
34-1*
1 Mean of 20 replicate wells.
2 % C-CytotoxiCity.
3 % B-Blocking.
4 Means in bold type serve as respective controls.
5 Not done.
* P<0.01.
NL
NL
NL
NL
NL
NL
A
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factors that potentiated cytotoxicity by
resident normal effector cells (ADCC,
Table II) present in the immune popu-
lation.
Demonstration of ADCC activity in
supernatants
Supernatants described-in Table I were
tested for ADCC activity. The data from
2 typical experiments summarized in
Table II illustrate that non-immune
lymphoid cells (NL) displayed significant
cytotoxicity for tumour cells that had
been previously exposed to supernatants
from NL treated with 100 ,ug of ILRNA
(33.9-40.7% ADCC) and TLRNA (27.1-
41.5% ADCC) when compared to control
supernatants (from NL treated with
NLRNA). As reported by Nelson et al.
(1975b) ADCC activity was also present in
supernatants of IL and TL. Peak activity
for RNA-treated lymphocytes (40.7-
41.5%) was confined to the 24 h and 48 h
periods, whilst supernatants from IL and
TL exhibited greatest ADCC activity at
72 h (47.2%) and 96 h (46.5%) respec-
tively. As with blocking activity, the rapid
decrease in production by RNA-treated
lymphocytes may be associated with the
decreased viability of these cells (Fig. 1).
Specificity offactors that block cell-mediated
immunity and potentiate ADCC
Fresh 48h supernatants were generated
from normal lymphocytes treated with
TLRNA and ILRNA as well as from TL
and IL. In addition, supernatants were
generated from normal lymphocytes
treated with splenic RNA from LM-cell-
immunized mice (LMRNA) and from
lymphocytes obtained directly from these
animals (ILM). All supernatants were
tested in a "criss-cross" pattern against
the 4198V and LM target cells. As can be
seen in Table III, supernatants arising
from RNA-treated lymphocytes exhibit-
ing blocking and ADCC activity for the
4198V tumour cell (Table III, A) did not
exert either effect on the LM target cell
(Table III, B). Likewise, supernatants
derived from LMRNA-treated cells dis-
Blocking
80
60
40
20
Supernatant from
NLt 50,jg TLRNA
unabsorbed
absorbed c LM cells
absorbed c 4198V tumour cells
FIG. 2.-Blocking of specific 4198V tumour-
cell cytotoxicity by supernatants from
normal lymphocytes (NL) treated with
50 and 100 ,ug of TLRNA before and after
absorption with 4198V or LM cells.
% blocking was calculated as described in
the text, with supernatants from NL treat-
ed with NLRNA as the control. Columns
represent the mean of 20 replicate wells
from 2 experiments and the bars represent
the range. Probability that the difference
between unabsorbed and 4198V-absorbed
groups were due to chance was <0 05.
Similar results were obtained from 3 addi-
tional experiments.
40
30-
ADCC 20
10
L
Supernatant from Supernatant from
NLt 100JI TLRNA NLt100ug ILRNA
unabsorbed
absorbed cLM cells
absorbed c 4198V tumour cells
FIG. 3.-ADCC activity for the 4198V tumour
cells associated with supernatants from
normal lymphocytes (NL) treated with
100 ,tg of TLRNA or ILRNA before and
after absorption with 4198V and LM cells.
% ADCC was calculated as described in the
text, with supernatants from NL treated
with NLRNA as the control. Columns
represent the mean of 20 replicate wells
from 2 experiments, and the bars represent
the range. Probability that the differences
between unabsorbed and 4198V-absorbed
groups were due to chance was <0-01.
Similar results were obtained from 3 addi-
tional experiments.
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playing ADCC activity for the LM cell
(Table III, B) failed to induce cytotoxicity
ofthe 4198V cells by the same mechanism
(Table III, A). Supernatants from TL,
IL and ILM exhibited a similar trend
when cross-tested. It is interesting to note
that no significant blocking activity was
associated with the supernatants gener-
ated against the LM cell. As this cell is not
tumorigenic, the absence of blocking
activity provides additional evidence for
the distinction between the tumour-
bearing and immune states described in a
similar fashion by Nelson et al. (1975a, b).
To illustrate further the specificity of
the elaborated factors, aliquots of super-
natants from RNA-treated cells shown in
Table III were absorbed with 107 LM or
4198V cells and retested for blocking and
ADCC activities. Results illustrated in
Fig. 2 show that blocking activity pro-
duced by lymphocytes treated with 50,ug
or lOO,ug of TLRNA was reduced signifi-
cantly (59.4% to 25.2% and 51.8% to
82% respectively) only when the super-
natants were absorbed with tumour cells
and not LM cells. Likewise, the LM cell
did not remove tumour-specific ADCC
activity. However, absorption with the
4198V cell reduced this activity from
28.8% to 4.4% and from 30.3%o to 2.8%
in supernatants from TLRNA- and
ILRNA-treated cells respectively (Fig. 3).
In similar experiments, ADCC activity for
the LM cellwas notremovedbyabsorption
with the 4198V cell but was completely
abolished after absorption with the LM
cell (data not shown).
Suppre88ion of cytotoxicity at the effector-
cell level by supernatantfluids
In previous experiments, TLRNA-in-
duced blocking activity was assessed at
the target-cell level by pretreating the
target cells with supernatants before the
addition of cytotoxic lymphocytes. In the
light of observations by Pope et al. (1976)
and Takei et al. (1976) who demonstrated
that immune responses could be sup-
pressed by soluble factors at the effector-
cell level, we designed experiments that
100
So8
%6
Suppression
60
40
20-
-2nJ
FIG. 4. Cytotoxic activity of 4198V-immune
lymphocytes after exposure to culture
supernatants from normal lymphocytes
(NL) treated with 50 (EJ) or 100 ,g
(i) of TLRNA or 100 ,tg of ILRNA
(U). % suppression was calculated in the
same fashion as blocking with control
supernatants from NL treated with
NLRNA. Columns represent the mean
of20 replicate wells from 2 experiments and
the bars represent the range. Probability
that the differences between the control and
test supernatants were due to chance was
<0-001 (50 jig TLRNA) and P<0 05
(100 ,ug TLRNA). Similar results were
obtained from 4 additional experiments.
would determine whether TLRNA con-
tained the information necessary to allow
normal lymphocytes to produce factors
capable of suppressing the cytotoxic
response of tumour-immune lymphocytes
(IL). IL were incubated for 30 min with
fresh 48h supernatants from RNA-treated
cells, washed and then tested on plated
4198V target cells. As can be seen in
Fig. 4, the cytotoxic activity of IL was
suppressed significantly (80%, P<0*001)
after exposure to supernatants from cells
treated with 50 -Kg of TLRNA, and was
,-20% higher than inhibition seen in
Table III when blocking (-60%) was
assessed at the target-cell level. Direct
suppression of cytotoxicity was also
apparent after IL exposure to super-
natants of cells treated with 100 ,tg of
TLRNA (27%, P<0 05) but, in contrast,
was considerably lower than blocking
activity shown in Table III (51-8%) with
the same dose of RNA. Taken together
these data suggest the presence of 2 dis-
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tinct factors capable of abolishing the
cytotoxic response, one operating at the
target-cell level and the other at the
effector-cell level. To clarify this point, the
TLRNA-induced supernatants were ab-
sorbed with the 4198V tumour cells and
retested for their capacity to directly
suppress or block cytotoxic activity. The
results (not shown) indicated that absorp-
tion did not interfere with suppression at
the effector-cell level, but significantly re-
duced the blocking activity to a degree
similar to that depicted in Fig. 2.
It is not surprising that treatment with
50 /zg of TLRNA produced greater sup-
pressor activity (Fig. 4) as we have en-
countered similar dose-dependent trans-
fers of other immunological responses
(RBC lytic antibody, cytotoxic T-cell,
lymphoblastogenesis, etc.). As with block-
ing, this type of suppression also appears
to be unique to the tumour-bearing state,
as normal lymphocytes treated with
lLRNA (Fig. 4) or LMRNA (not shown)
failed to produce a similar suppressor
factor in culture.
DISCUSSION
It is clear that normal lymphocytes
treated with proper doses of RNA isolated
from spleens of tumour-bearing (TLRNA)
or tumour-immune (ILRNA) mice pro-
duced factors that potentiated ADCC
(Table II), whereas only those treated
with TLRNA produced soluble "blocking"
(Table I) and "suppressor" (Fig. 4)
factors. These results indicate that RNA
faithfully transfers those differences re-
ported by others (Nelson et al., 1975a, b;
Pope et al., 1976; Takei et al., 1976) for
lymphocytes taken directly from tumour-
bearing and tumour-immune animals. It
should not be surprising that suppressor
activity is transferred along with the
capacity to produce a wide variety of
humoral and cell-mediated immune fac-
tors, if it is assumed that RNA contains
the total information necessary for im-
mune responses, including RNA from
suppressor cells.
Numerous reports have established that
the presence of a tumour stimulates the
release of factors from lymphocytes and
macrophages which are capable of sup-
pressing immune activity at either the
tumour target-cell or effector-cell level.
The data reported in this study indicate
that TLRNA contains the information for
the production of at least 2 factors that
suppress tumour-cell cytotoxicity by im-
mune lymphocytes. The suppressor
activity exerted at the tumour-cell level,
illustrated in Table I, is most likely the
so-called "blocking antibody" which has
been described by others (Nelson et al.,
1975a; Takasugi & Klein, 1971). Two
observations suggested that this factor is
tumour-specific: (1) supernatant blocking
activity was reduced significantly
(P<001) after absorption with the 4198V
cell but not the LM cell (Fig. 2); and (2)
supernatants blocking tumour-cell de-
struction were incapable of inhibiting
LM-cell cytotoxicity by LM-immune
lymphocytes (Table III). The failure to
absorb the suppressor activity exerted at
the effector-cell level (Fig. 4) does not
preclude the possibility that this factor is
tumour-specific, since it was elicited from
lymphocytes treated with tumour-specific
RNA. However, several unpublished ob-
servations in our laboratory suggest in-
directly that this type of suppression may
be nonspecific. First, it was found that
supernatants from lymphocytes treated
with TLRNA contained a factor that was
capable of suppressing the plaque-forming
cell (PFC) response of mouse lymphocytes
to sheep red blood cells (SRBC). Secondly,
supernatants generated from cultures of
peripheral blood lymphocytes from cancer
patients (analogous to TL in this study)
also suppressed the PFC response to
SRBC. At this point we can hypothesize
that the nonspecific factor suppressing
PFC responses, especially in the case of
TLRNA-treated cells, may be similar to
the factor suppressing cell-mediated im-
munity described in this study. However,
we are aware that on the data available
this is mere speculation, since we have
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neither determined the source of the
factor(s) (lymphocyte? macrophage?) nor
the mechanism of action. Finally, we have
observed that the direct treatment of
alloantigen-sensitized lymphocytes with
TLRNA nonspecifically suppressed the
appearance of PFC and cytotoxic T-cell
generation for an unrelated cell line. The
mechanism for this type of suppression
(factor?) is unknown to us at this time,
but apparently the phenomenon is asso-
ciated with the tumour-bearing state,
since RNA from immune animals fails to
modify the same immunological responses.
All these data together indicate that non-
specific as well as specific suppressor
activity can be transferred to normal
lymphocytes with TLRNA. Whether or
not the nonspecific suppressor activities
are due to the same or different factor(s),
operating by a similar or different mech-
anism, is currently being investigated.
The establishment of absolute tumour
specificity for all of these factors necessi-
tates further experimentation with other
unrelated tumour cell lines. However, we
believe that the absence ofsuch data from
this report does not detract from the
central theme of the investigation, which
was to establish the ability to transfer
suppressive immunological activity with
RNA.
In recent years the possibility of using
"immune" RNA as an immunotherapeutic
agent for cancer has diminished con-
siderably. We believe that this study, and
others current in our laboratory, provide
the basis for a more effective application
ofRNA as a tool to study various immuno-
logical responses. At the initiation of this
study we deliberately designed experi-
ments that would demonstrate the capa-
city to transfer suppressive immunological
activity. The implication here is that this
transfer is possible and not an artefact,
since suppression can only be transferred
with RNA from an immunologically sup-
pressed state (tumour-bearing). In future
studies we hope to use this information as
a basis for investigating mechanisms by
which the immune response is modulated
(activated or suppressed). The application
of RNA in this manner may provide im-
portant information about the immune
response in general and help to charac-
terize immunological systems for which
only little information is available.
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National Cancer Institute, National Institutes of
Health No. CA-16867, The Ohio Division of the
American Cancer Society, and The Ohio State
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